louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04118205: REtinaL Imaging & Ambulatory BLood PrEssure
Official title: REtinaL Imaging & Ambulatory BLood PrEssure: Validating Ultra-widefield Retinal Imaging Derived Biomarkers Against Ambulatory Blood Pressure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Blood Pressure
Lead sponsor: University of Edinburgh
Sponsor class: OTHER
Collaborators: name: Optos, PLC
name: NHS Lothian
First posted: 2019-10-08
Enrollment: 591
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants attending a hypertensive clinic at the Western General Hospital in Edinburgh will be asked to consent to ultra-wide field retinal imaging, subject to the inclusion and exclusion criteria below. It is expected that between 25 and 50 participants per week attend the clinic, of which approximately 50% are attending without a known diagnosis of hypertension.

Brief summary: High blood pressure is a common condition which generally does not have any symptoms. Its estimated that around one third of people with high blood pressure do not know they have it. The back of the eye called the retina is one of the few places in the human body allowing easy observation of blood vessels. This study aims to see if simple non-invasive imaging of the blood vessels of the retina will highlight people with high blood pressure.

Detailed description: This will be a prospective, single centre study recruiting patients who are attending the ambulatory blood pressure clinic at the Western General Hospital. Suitable patients will be approached, and if they consent will have pictures of the back of each of their eyes taken. These pictures will then be reviewed, with certain measurements taken of the small blood vessels which can been seen at the back of the eye. These measurements will then be compared to the participants blood pressure readings to see if they might accurately correlate to blood pressure.

Eligibility criteria: Inclusion Criteria:

* Attending ambulatory blood pressure clinic
* Able to undertake ambulatory BP measurement
* Able to undertake single clinic-based BP measurement
* Able to undergo UWF retinal imaging with a SLO
* Aged 18 to 90
* Able to give informed consent

Exclusion Criteria:

* People with known history of retinal surgery
* People under the age of 18 years.
* People that cannot: manoeuvre themselves to the SLO unaided, sit upright in a chair or wheelchair or position themselves comfortably for imaging.
* People with epilepsy

Primary outcomes:
measure: Does retinal arteriovenous ratio correlate to systolic blood pressure
timeFrame: 1 day
Secondary outcomes:
measure: Does retinal arteriovenous ratio correlate to clinic systolic blood pressure
timeFrame: 1 day
Other outcomes:
Locations:
city: Edinburgh
country: United Kingdom
facility: Clinical Research Centre, Western General Hospital
state: City Of Edinburgh
Study officials:
References:
Clinical trial NCT06783205: Does Restriction of the Dominant Hand Due to Injury Improve Non-Dominant Hand Function?
Official title: Does Restriction of the Dominant Hand Due to Injury Improve Non-Dominant Hand Function?
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Dexterity
Tendon Injuries
Fractures
Nerve Injury
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2025-01-20
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients referred to the Hand Rehabilitation Unit of Gazi University, Faculty of Health Sciences, for physiotherapy and rehabilitation due to hand-related pathologies, and who meet the inclusion and exclusion criteria will be included.

Brief summary: Hand injuries result in the restriction of use of the injured hand within a splint or a plaster during the first 6 weeks which is critical for tissue healing. When the dominant hand is injured, patients experience more difficulty in daily life due to this restriction. Patients injured on their dominant hand mostly express that they are forced to use their non-dominant hand in their activities and as a result, the function of the non-dominant hand improves. However, the non-dominant hand function has not been analyzed in patients with restricted use of the dominant hand during the tissue healing period.


Eligibility criteria: Inclusion Criteria:

* Individuals who need to use a splint for 6 weeks due to any pathology in their dominant hand
* Ages between 18-65
* Individuals who are within the first 10 days after the operation

Exclusion Criteria:

* Individuals with an isolated thumb injury
* Those who require bilateral use of the splint/have bilateral pathology
* Those who have a condition that prevents the use of the non-dominant hand
* Those who can use both hands equally/do not have a dominant side (ambidextrous/two-handed)
* Those who have a cooperative status that will not comply with the treatment program
* Data from individuals who do not use the splint as described during the 6-week follow-up period will not be included in the analysis.

Primary outcomes:
measure: hand function
timeFrame: 6 weeks
Secondary outcomes:
measure: disability level
timeFrame: 6 weeks
measure: Grip and pinch strengths
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University Health Science Faculty Physiotherapy and Rehabilitation Department
state: Yenimahalle
Study officials:
References:
Clinical trial NCT01162005: Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children
Official title: Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Nephrotic Syndrome
Keywords: Primary Nephrotic syndrome
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Chong Kun Dang Pharmaceutical
First posted: 2010-07-14
Enrollment: 77
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the efficacy of tacrolimus in the management of NS(nephrotic syndrome) , the investigators designed this prospective study. The investigators will enroll 100 children with NS(frequent relapse steroid dependent NS, steroid resistance NS) who will be treated with tacrolimus (0.1-0.2 mg/kg/day in two divided doses over 12 h adjusted to a trough level between 5 and 10 ng/ml) for 12 months in combination with low-dose steroids. Other therapies will be included angiotensin-converting enzyme inhibitors, antihypertensive drugs, multivitamins and lipid-lowering agents.

Follow-up is every second week for the first 4 weeks, then monthly. After initiation of tacrolimus therapy, blood was drawn each visit to determine tacrolimus trough levels.

Detailed description: Subsequently , monthly measurements were made until stable levels of tacrolimus were achieved. Urine was analyzed for proteinuria at each visit. Serum creatinine, glucose, albumin and alanine aminotransferase were measured and complete blood counts were obtained at each visit during the study.

Eligibility criteria: Inclusion Criteria:

* Frequent relapse nephrotic syndrome
* steroid resistance nephrotic syndrome

Exclusion Criteria:

* secondary nephrotic syndrome
* estimated glomerular filtration rate \< 60 mL/min/1.73m2
* with active hepatitis

Primary outcomes:
measure: Remission Rate
timeFrame: 12-month treatment period
Secondary outcomes:
measure: Duration of Remission
timeFrame: 12-month treatment period
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National Children's Hospital
name: ILSOO Ha, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01558505: Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation
Official title: Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Critical Limb Ischemia
Keywords: critical limb ischemia
drug-eluting balloon
restenosis
Lead sponsor: Ospedale San Donato
Sponsor class: OTHER
First posted: 2012-03-20
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Drug-eluting balloon showed positive results in terms of restenosis reduction in peripheral intervention (PTA). The aim of the study is to investigate in a randomized fashion the efficacy and safety of Paclitaxel-eluting balloon (PEB) (In.Pact Amphirion, Invatec, Brescia, Italy) versus non drug-eluting balloon (NEB) (Amphirion deep, Invatec, Brescia, Italy) in diabetic patients with Critical Limb Ischemia (CLI) undergoing PTA of below-the-knee (BTK) vessels.


Eligibility criteria: Inclusion Criteria:

* age\>18 years
* angiographic stenosis\>50% or occlusion of one below-knee vessel

Exclusion Criteria:

* allergy to Paclitaxel
* contraindication for combined antiplatelet treatment
* life expectancy \<1 year
* hypersensitivity or contraindication to one of the study drugs
* lack of consent
* need for amputation

Primary outcomes:
measure: angiographic binary restenosis
timeFrame: 12 months
Secondary outcomes:
measure: major amputation
timeFrame: 24 motnhs
measure: target lesion revascularization
timeFrame: 24 months
measure: vessel reocclusion
timeFrame: 24 months
Other outcomes:
Locations:
city: Arezzo
country: Italy
facility: Cardiovascular Department, Ospedale S.Donato
state: AR
Study officials:
References:
citation: Liistro F, Porto I, Angioli P, Grotti S, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G, Bolognese L. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013 Aug 6;128(6):615-21. doi: 10.1161/CIRCULATIONAHA.113.001811.
Clinical trial NCT03590405: Uterus Transplantation LD - Feasibility Study - Sahlgrenska - BMC
Official title: Uterus Transplantation LD - Feasibility Study - Sahlgrenska - Bellevue Medical Centre
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mrk Anomaly
Infertility, Female
Keywords: uterus
infertility
transplantation
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
Collaborators: name: Saint Joseph University, at Bellevue Medical Centre
First posted: 2018-07-18
Enrollment: 2
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Medical know-how concerning uterus transplantation will be transferred to new site by structured process involving theory, animal workshops and a clinical feasibility study on human subjects.

Detailed description: Medical know-how concerning uterus transplantation will be transferred to new site by structured process involving theory, animal workshops and surgery.

Theory and common animal workshops have been ongoing for 3 years. The team from Bellevue Medical Centre is affiliated to St Joseph, University, Beirut

Eligibility criteria: Inclusion criteria recipient

* age \< 38 years
* psychologicaly stable
* BMI \< 35
* no systemic disease
* no standing medication
* in a stable relationship or married
* normal ovarian reserve
* absolute uterine factor infertility
* normal kidney function

Inclusion criteria donor

* close relative to recipient
* age \< 60 years
* normal pregnancies
* maximum two cesarean sections
* BMI \< 35
* no major systemic disease
* no previous major surgery

Primary outcomes:
measure: live birth
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Sahlgrenska University Hospital
city: Göteborg
country: Sweden
facility: Mats Brännström
Study officials:
affiliation: Sahlgrenska University Hospital
name: Mats Brännström, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06410105: Orthodontic Treatment With Clear Aligner
Official title: Three-dimensional Assessment of Root Resorption Following Treatment With Clear Aligners Using Cone Beam Computed Tomography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Orthodontic Pathological Resorption of External Root
Keywords: Orthodontic, clear aligners, fixed appliances, CBCT
Lead sponsor: Tishreen University
Sponsor class: OTHER
First posted: 2024-05-10
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: : Crossover Assignment A randomized, controlled, crossover, double-blind clinical study, Comparison of
Primary purpose: TREATMENT

Brief summary: Three-dimensional Assessment of Root Resorption following treatment with clear aligners using Cone Beam Computed Tomography Design: A randomized, controlled, crossover, double-blind clinical study including twenty six adult , aged 18-25 years old.

Detailed description: Orthodontically induced root resorption is one of the common undesirable sequalae of orthodontic treatment. one third of the patients treated with fixed appliances showed more than 3 mm of root resorption whereas at least 2% of orthodontic patients showed more than 5 mm of root resorption.

There is a controversy in the literature regarding the effect of clear aligners on apical root resorption. One previous study reported that some kinds of removable aligners may have the potential of minimizing orthodontic ally induced root resorption due to the studied piezoelectric property by these materials Till now, the degree of apical root resorption following treatment with (in house) aligners has not been reported in the literature.

Eligibility criteria: Inclusion Criteria:

The Clinical Diagnosis the age of patients ranges between 18-25 years, medium crowding between 3-6 mm in the area of the upper anterior teeth according to Little irregularity index 20,class1 according angel classification healthy patient No previous orthodontic treatment vital teeth with periodontal tissue without root absorption,

Exclusion Criteria:

Previous history of orthodontic or orthopedic treatment. Presence of craniofacial anomalies. Presence of any signs and symptoms of gingival and periodontal diseases. Presence of significant medical history (including drug allergy). Pregnant and lactating women

Primary outcomes:
measure: treatment with clear aligners
timeFrame: two years
Secondary outcomes:
measure: comparative study of Buccolingual Inclination changes
timeFrame: two years
Other outcomes:
Locations:
city: Latakia
country: Syrian Arab Republic
facility: Tishreen University
Study officials:
affiliation: Tishreen University
name: fadi khalil, prof
role: STUDY_CHAIR
References:
Clinical trial NCT00851305: Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy
Official title: Comparison Confocal Laser Endomicroscopy With Conventional Endoscopy for the Detection of Early Gastric Cancers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stomach Neoplasms
Precancerous Conditions
Keywords: Stomach
endoscopy
neoplasms
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2009-02-25
Enrollment: 1786
Sex: ALL
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to determine whether endomicroscopy can improve the detection of Early Gastric Cancers (EGC).

Detailed description: Endoscopy is proved to be the best method to achieve early diagnosis of gastric cancer (GC). Confocal laser endomicroscopy (CLE), a new diagnostic modality, has been shown to be valuable in increasing the diagnostic yield of colorectal neoplasias, but it is not clear whether CLE is helpful to find out early gastric cancer (EGC).The aim of the study is to investigate the value of CLE in improving the detection of EGCs.

Eligibility criteria: Inclusion Criteria:

* 45 years old ≤ age \< 80 years old
* Patients with dyspeptic symptoms or with gastric premalignant conditions for surveillance gastroscopy

Exclusion Criteria:

* Known cancers or gastrectomy
* Scheduled for endoscopic treatment
* Alarm symptoms such as dysphagia, anaemia, gastrointestinal bleeding or obstruction, marked weight loss
* Under conditions such as:

  * ascites
  * jaundice
  * liver cirrhosis
  * impaired renal function
  * coagulopathy
  * fever
  * pregnancy
  * breastfeeding
* Inability to provide informed consent
* Known allergy to fluorescein sodium

Primary outcomes:
measure: To compare the rate of EGCs/GCs using CLE versus conventional gastroscopy.
timeFrame: one year
Secondary outcomes:
measure: To evaluate the efficacy of in vivo CLE on different pathological characteristics of EGCs.
timeFrame: one year
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Gastroenterology, Qilu Hospital, Shandong University
state: Shandong
Study officials:
affiliation: Department of Gastroenterology, Qilu Hospital, Shandong University
name: Yanqing Li, PhD. MD.
role: STUDY_DIRECTOR
References:
Clinical trial NCT03040505: Future Mental Projections in Schizophrenia
Official title: Future Mental Projections in Schizophrenia
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Schizophrenia
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2017-02-02
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with Schizophrenia

Brief summary: The aim of the study is to investigate temporal organization of future thinking in patients with schizophrenia. Patients and control participants will be asked to envision and briefly describe ten personal future events using a cue-words list. Then they will be asked to describe everything that came to their minds (i.e. to think aloud) while they attempted to determine when an event will likely occur. The investigators will compare the proportion of several predefined strategies mentioned by the two groups of participants to locate future events in time. The investigators predict that patients will envision less personal future events and will rely to a lesser extent on strategies to locate events in time, than control participants.


Eligibility criteria: Inclusion Criteria:

* for patients only
* male or female
* age limits : 18-55 years old
* under the protection of health insurance
* who have signed up the consent form
* schizophrenia or schizo-affective disorder according to the DSM-5 criteria (APA, 2013).
* clinically stable for at least 2 months
* patients under guardianship or curatorship need agreement of their legal representative
* informed of the results of prior medical examination for controls only
* male or female
* age limits : 18-55 years old
* under the protection of health insurance
* who have sign up the consent form
* recruited from the general population and matched on gender, age years of schooling
* no psychiatric history (DSM-5)

Exclusion Criteria:

* for both patients and controls
* current severe or unstable somatic illness
* neurological history (brain injury \> 15 minutes loss of consciousness , epilepsia, brain surgery...)
* current substance use disorder (DSM-5)
* current major depressive disorder (CDSS,BDI, HDRS)
* mental retardation (IQ \< 70, WAIS-4, f-NART)
* history of general anesthesia 3 months prior to the experiment
* pregnancy declared by the subject
* breast feeding
* current legal control
* in emergency situation
* included during exclusion period in another experiment
* for controls only
* taking of antipsychotic drugs for the 3 weeks prior to inclusion
* under guardianship or curatorship

Primary outcomes:
measure: Number of time location strategies
timeFrame: 1 months
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de psychiatrie 1
Study officials:
References:
Clinical trial NCT00886405: Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer
Official title: Phase II Study That Evaluates Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Locally Advanced Non Small-Cell Lung Canger
Keywords: Nitroglycerin
Locally advanced non small-cell lung cancer
Vascular endothelial growth factor
Hypoxia Inducible Factor
Clinical stage IIIA and/or IIIB (without pleural effusion)
Lead sponsor: National Institute of Cancerología
Sponsor class: OTHER_GOV
First posted: 2009-04-22
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Nitroglycerin will increase the effectiveness of treatment with induction chemotherapy and concurrent chemo-radiotherapy by reducing chemo-radio resistance through an increased oxygen pressure in tumoral tissue. The combination treatment of nitroglycerin and chemotherapy will result in longer disease-free and over-all survival in patients with locally advanced NSCLC

Detailed description: Nitroglycerin decreases hypoxia-induced resistance to antitumor drugs due to inhibition of Hypoxia Inducible Factor alfa (HIF-1α), it increases oxygen pressure in tumoral tissue by augmenting tumor blood flow, increases apoptosis, activation of p53, and induces cellular growth inhibition. Randomized studies showed that the addition of transdermal nitroglycerin to non small cell lung cancer (NSCLC) patients with metastasis treated with vinorelbine and cisplatin achieved a significantly better global response to treatment than conventional treatment

Eligibility criteria: Inclusion Criteria:

* Histopathologic diagnosis of non small-cell lung cancer
* Clinical stage IIIA and/or IIIB without pleural effusion
* ECOG functional status 0 or 1
* No renal function alteration (GFR \>50%)
* No hepatic function alteration (ALT and AST less than 2 times its normal value)
* Leucocytes more than 2,000/mcl
* Hemoglobin more than 10mg/dL
* Platelets more than 100,000/mcl

Exclusion Criteria:

* Ischemic heart disease
* Abnormal electrocardiogram

Primary outcomes:
measure: Time to progression, over-all survival
timeFrame: 5 years
Secondary outcomes:
measure: Levels of oxidative stress through lipid peroxidation and quantification of VEGF Toxicity from treatment with chemotherapy and concurrent chemo-radiotherapy combined with transdermal nitroglycerin
timeFrame: 5 years
Other outcomes:
Locations:
city: Mexico city
country: Mexico
facility: National Institute of Cancerología
state: Distrito federal
Study officials:
affiliation: National Counsil of Science and Technology
name: Oscar A Rodriguez, MD
role: PRINCIPAL_INVESTIGATOR
References: